09:27 AM EST - BioVaxys Technology Corp : Announces it has executed a binding Letter of Intent with AP Visionaries, Inc. of Ontario to jointly develop a proprietary DPX™ formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp
shares C.BIOV are trading down one cent at $0.07.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACNX&qmodStoryID=7702152714673336
